The role of Toll-like receptors in chemoradiotherapy-induced gastrointestinal mucositis
10.12016/j.issn.2096-1456.2021.02.010
- Author:
JI Ling
1
,
2
,
3
;
WANG Jiahe
1
,
2
,
3
;
WANG Jiantao
4
,
5
,
6
;
Wang Yan
1
,
2
,
7
Author Information
1. State Key Laboratory of Oral Diseases &
2. National Clinical Research Center for Oral Diseases &
3. West China Hospital of Stomatology, Sichuan University
4. State key Laboratory of Biotherapy &
5. Department of Lung Cancer Center and Department of Radiation Oncology &
6. West China Hospital, Sichuan University
7. Department of Pediatric Dentistry West China Hospital of Stomatology
- Publication Type:Review
- Keywords:
Toll-like receptor (TLR）;
oral mucositis;
gastrointestinal mucositis;
chemotherapy;
radiotherapy;
TLR2;
TLR4;
TLR5;
TLR9
- From:
Journal of Prevention and Treatment for Stomatological Diseases
2021;29(2):124-129
- CountryChina
- Language:Chinese
-
Abstract:
Mucositis is a common gastrointestinal complication in cancer patients undergoing chemoradiotherapy, including oral mucositis and gastrointestinal mucositis, with clinical manifestations of oral ulcers, vomiting, diarrhea and pain that seriously reduce the quality of life of patients and even affect anticancer therapy. Toll-like receptor (TLR) are important receptors involved in innate immunity and in the development of chemoradiation-induced mucositis by mediating the effect between microorganisms and the host. A comprehensive understanding of the role of TLR in mucositis is helpful to guide the prevention and treatment of mucositis. This paper reviews the available studies on TLR and mucositis. The results of the literature review indicate that different TLR have different roles in chemoradiation-induced mucositis: TLR2 is an important receptor in the inflammatory cascade of chemoradiation-induced mucositis; TLR4 activation can increase gastrointestinal mucosal inflammation and lead to oral epithelial ulceration; TLR5 agonists can reduce the degree of radiation-induced mucositis damage; and antagonizing or knocking out TLR9 can reduce chemoradiation-induced gastrointestinal mucositis. However, no TLR agonists or inhibitors have yet been applied in clinical practice, and additional studies are needed to explore the role of different TLR in mucositis in the future to provide a reference for the precise prevention and treatment of chemoradiation-induced mucositis.
- Full text:Toll样受体在放化疗诱导的消化道黏膜炎中的作用.pdf
